The Role of Telomerase in Breast Cancer's Response to Therapy

Int J Mol Sci. 2022 Oct 25;23(21):12844. doi: 10.3390/ijms232112844.

Abstract

Currently, breast cancer appears to be the most widespread cancer in the world and the most common cause of cancer deaths. This specific type of cancer affects women in both developed and developing countries. Prevention and early diagnosis are very important factors for good prognosis. A characteristic feature of cancer cells is the ability of unlimited cell division, which makes them immortal. Telomeres, which are shortened with each cell division in normal cells, are rebuilt in cancer cells by the enzyme telomerase, which is expressed in more than 85% of cancers (up to 100% of adenocarcinomas, including breast cancer). Telomerase may have different functions that are related to telomeres or unrelated. It has been shown that high activity of the enzyme in cancer cells is associated with poor cell sensitivity to therapies. Therefore, telomerase has become a potential target for cancer therapies. The low efficacy of therapies has resulted in the search for new combined and more effective therapeutic methods, including the involvement of telomerase inhibitors and telomerase-targeted immunotherapy.

Keywords: breast cancer; resistance; telomerase; therapy.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Humans
  • Immunotherapy
  • Neoplasms* / pathology
  • Telomerase* / metabolism
  • Telomere / metabolism

Substances

  • Telomerase
  • Enzyme Inhibitors

Grants and funding

This work was funded by Poznan University of Medical Sciences.